Comparative effectiveness of two metronomic chemotherapy schedules-our experience in the preclinical field

Cancer Investigation

Volumn 32, Issue 3, 2014, Pages 92-98

  Rico, M J ^a   Perroud, H A ^a   Mainetti, L E ^a,b   Rozados, V R ^a   Scharovsky, O G ^a  

^a UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Celecoxib; Combined treatment; Cyclophosphamide; Doxorubicin; Mammary adenocarcinomas; Metronomic chemotherapy

Indexed keywords

CELECOXIB; CYCLOPHOSPHAMIDE; DOXORUBICIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; BREAST ADENOCARCINOMA; BREATHING; CANCER COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; FEMALE; FOOD INTAKE; LEUKOCYTE COUNT; LUNG METASTASIS; METASTASIS INHIBITION; METRONOMIC DRUG ADMINISTRATION; MOTOR ACTIVITY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; STIMULUS RESPONSE; TUMOR VOLUME;

ANALYSIS OF VARIANCE; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; FEMALE; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NEOPLASM METASTASIS; TUMOR BURDEN;

EID: 84893503335     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357907.2013.877480     Document Type: Article

References (39)

1. den Hollander P, Savage MI, Brown PH. Targeted Therapy for Breast Cancer Prevention. Front Oncol 2013;3:250.
2. Vinayak S, Carlson RW. mTOR inhibitors in the treatment of breast cancer. Oncology (Williston Park) 2013;27:38-44, 6, 8 passim.
3. Botrel TE, Paladini L, Clark OA. Lapatinib plus chemotherapy or endocrine therapy (CET) versus CET alone in the treatment of HER-2-overexpressing locally advanced or metastatic breast cancer: systematic review andmeta-analysis. Core Evid 2013;8:69-78.
4. Baselga J, Cort́es J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM, CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366:109-119.
5. Gampenrieder SP, Rinnerthaler G, Greil R. Neoadjuvant chemotherapy and targeted therapy in breast cancer: past, present, and future. J Oncol 2013;2013:732047.
6. Boyraz B, Sendur MA, Aksoy S, Babacan T, Roach EC, Kizilarslanoglu MC, Petekkaya I, Altundag K. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. Curr Med Res Opin 2013;29:405-414.
7. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Díeras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K, EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-1791.
8. Scharovsky OG, Mainetti LE, Rozados VR. Metronomic chemotherapy: changing the paradigm that more is better. Curr Oncol 2009;16:7-15.
9. Pasquier E, Kavallaris M, Andre N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 2010;7: 455-465.
10. Rozados VR, Mainetti LE, Rico MJ, Zacarias Fluck MF, Matar P, ScharovskyOG. The immune response and the therapeutic effect ofmetronomic chemotherapy with cyclophosphamide. Oncol Res 2010;18:601-605.
11. Mainetti LE, Rico MJ, Ferńandez-Zenobi MV, Perroud HA, Roggero EA, Rozados VR, Scharovsky OG. Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomas. Ann Oncol 2013;24:2310-2316.
12. Masferrer J. Approach to angiogenesis inhibition based on cyclooxygenase-2. Cancer J 2001;7(Suppl 3):S144-S150.
13. Masferrer JL. Cyclooxygenase-2 inhibitors in cancer prevention and treatment. Adv Exp Med Biol 2003;532:209-213. (Pubitemid 37179999)
14. Basu GD, Pathangey LB, Tinder TL, Lagioia M, Gendler SJ, Mukherjee P. Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res 2004;2:632-642. (Pubitemid 39557666)
15. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-436. (Pubitemid 38745528)
16. Taromaru GC, DE Oliveira VM, Silva MA, Montor WR, Bagnoli F, Rinaldi JF, Aoki T. Interaction between cyclooxygenase-2 and insulin-like growth factor in breast cancer: a new field for prevention and treatment. Oncol Lett 2012;3:682-688.
17. Wang D, Dubois RN. Cyclooxygenase-2: a potential target in breast cancer. Semin Oncol 2004;31:64-73. (Pubitemid 38543941)
18. Shiraga E, Barichello JM, Ishida T, Kiwada H. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonarymetastaticmouse model. Int J Pharm2008;353:65-73.
19. Dellapasqua S,Mazza M, Rosa D, Ghisini R, Scarano E, Torrisi R, Maisonneuve P, Viale G, Cassano E, Veronesi P, Luini A, Goldhirsch A, Colleoni M. Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer. Breast 2011;20:319-323.
20. Mainetti LE, Rozados VR, Rossa A, Bonfil RD, Scharovsky OG. Antitumoral and antimetastatic effects of metronomic chemotherapy with cyclophosphamide combined with celecoxib on murine mammary adenocarcinomas. J Cancer Res Clin Oncol 2011;137: 151-163.
21. CanadianCouncil onAnimalCare.CCACguidelines on: procurement of animals used in science. Ottawa, ON: CCAC, 2007.
22. Squartini F, Pingitore R. Tumours of the mammary gland. IARC Sci Publ 1994:47-100.
23. Klement G, Baruchel S, Rak J,Man S, ClarkK,HicklinDJ, Bohlen P, Kerbel RS. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15-R24. (Pubitemid 30217701)
24. Browder T, ButterfieldCE,Kr̈aling BM, Shi B,Marshall B,O'Reilly MS, Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-1886. (Pubitemid 30207647)
25. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005;23:939-952. (Pubitemid 46202314)
26. Yap R, Veliceasa D, Emmenegger U, Kerbel RS, McKay LM, Henkin J, Volpert OV. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy. Clin Cancer Res 2005;11:6678-6685. (Pubitemid 41339009)
27. Emmenegger U, Morton GC, Francia G, Shaked Y, Franco M, Weinerman A,Man S, Kerbel RS. Low-dosemetronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia. Cancer Res 2006;66:1664-1674. (Pubitemid 43259951)
28. Zhang M, Tao W, Pan S, Sun X, Jiang H. Low-dose metronomic chemotherapy of paclitaxel synergizes with cetuximab to suppress human colon cancer xenografts. Anticancer Drugs 2009;20:355-363.
29. duManoir JM, Francia G,Man S,Mossoba M,Medin JA, Viloria-Petit A, Hicklin DJ, Emmenegger U, Kerbel RS. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res 2006;12:904-916.
30. Navid F, Baker SD, McCarville MB, Stewart CF, Billups CA,Wu J, Davidoff AM, Spunt SL, Furman WL, McGregor LM, Hu S, Panetta JC, Turner D, Fofana D, Reddick WE, Leung W, Santana VM. Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors. Clin Cancer Res 2013;19:236-246.
31. Munoz R, Man S, Shaked Y, Lee CR, Wong J, Francia G, Kerbel RS. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFTcyclophosphamide metronomic chemotherapy. Cancer Res 2006; 66:3386-3391.
32. Ma J,WaxmanDJ. Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Mol CancerTher 2008;7:79-89.
33. Shevchenko I, Karakhanova S, Soltek S, Link J, Bayry J,Werner J, Umansky V, Bazhin AV. Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. Int J Cancer 2013;133:98-107.
34. Buckstein R, Kerbel RS, Shaked Y, Nayar R, Foden C, Turner R, Lee CR, Taylor D, Zhang L, Man S, Baruchel S, Stempak D, Bertolini F, Crump M. High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res 2006;12:5190-5198. (Pubitemid 44453348)
35. Fontana A, Galli L, Fioravanti A, Orlandi P, Galli C, Landi L, Bursi S, Allegrini G, Fontana E, Di Marsico R, Antonuzzo A, D'Arcangelo M, Danesi R, Del Tacca M, Falcone A, Bocci G. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer. Clin Cancer Res 2009;15: 4954-4962.
36. Perroud HA, Rico MJ, Alasino CM, Queralt F, Mainetti LE, Pezzotto SM, Rozados VR, Scharovsky OG. Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients. Future Oncol 2013;9:451-462.
37. Montagna E, Cancello G, Torrisi R, Rizzo S, Scarano E, Colleoni M. Lapatinib and metronomic capecitabine combination in an HER2-positive inflammatory breast cancer patient: a case report. Ann Oncol 2010;21:667-668.
38. Huijts CM, Santegoets SJ, van den Eertwegh AJ, Pijpers LS, Haanen JB, de Gruijl TD, Verheul HM, van der Vliet HJ. Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer. BMC Cancer 2011;11:505.
39. Tong DK, Cheng CW, Ching Chan S, Ngor Wong L, Chow LW. Phase II study of an 'all-oral' regimen of capecitabine, idarubicin and cyclophosphamide for metastatic breast cancer-safety, efficacy and quality of life. Oncology 2005;68:520-525. (Pubitemid 41160985)